Trump’s $1.8B “anti-weaponization” fund collapses—does the tax-audit shield stay?

On June 2, 2026, acting U.S. Attorney General Todd Blanche said the Trump administration is not moving forward with a planned $1.8 billion “Anti-Weaponization Fund,” despite it being framed as compensation for people who claimed the justice system was “weaponized.” Blanche’s remarks, reported across multiple outlets, directly contradict the earlier push for the fund and signal a rapid policy reversal. In parallel, U.S. officials continued an agreement that bars the government from probing past tax filings from President Donald Trump and his businesses. Reuters sources indicated that even as the weaponization fund fell into doubt, Trump would likely keep tax audit immunity. Strategically, the episode is less about a single pot of money and more about the administration’s approach to accountability, prosecutorial independence, and the political contest over “weaponization” narratives. By pausing the compensation mechanism, the government reduces exposure to claims that it is admitting wrongdoing while still preserving a separate legal shield around tax scrutiny. This creates a dual-track dynamic: one track withdraws a high-visibility remedial program, while another track maintains constraints on investigative reach. The likely beneficiaries are Trump and his business interests, while critics—especially those who argued the justice system was selectively targeted—lose a concrete, funded pathway for compensation. Market and economic implications are indirect but potentially meaningful through risk premia in U.S. legal-policy uncertainty and corporate governance expectations. If tax audit immunity remains, it can reduce near-term compliance and litigation risk for Trump-linked entities, which may support sentiment around related private-market exposures and any firms with perceived political entanglement. Conversely, scrapping the compensation fund could heighten political volatility and increase the probability of future legal challenges, which typically lifts the cost of capital for affected sectors through higher uncertainty. The most immediate “instrument” impact is likely in sentiment-driven areas—U.S. equities and credit spreads sensitive to governance and regulatory risk—rather than in commodities or FX, though USD volatility could rise modestly if the dispute escalates into broader institutional conflict. What to watch next is whether the administration formalizes the pause with legal documentation and whether Congress or courts challenge the tax-audit immunity agreement. Key indicators include additional testimony by Blanche, any Department of Justice guidance on the fund’s status, and reporting on the scope and duration of the tax-filing probe restrictions. A trigger point would be renewed movement toward a replacement compensation mechanism or, alternatively, a court ruling that narrows the immunity arrangement. Over the next days to weeks, escalation risk will hinge on whether allies’ criticisms intensify and whether the “weaponization” debate expands into broader investigations, hearings, or sanctions-like regulatory actions.

Geopolitical Implications

• 01

  The episode intensifies the U.S. domestic institutional legitimacy contest over “justice system weaponization,” which can spill into broader governance and regulatory credibility.

• 02

  Maintaining tax-audit immunity while dropping a compensation fund suggests a strategy to reduce litigation and political exposure without conceding accountability.

• 03

  If legal constraints are perceived as selective, it can raise the probability of sustained political conflict that indirectly affects investor confidence in U.S. rule-of-law stability.

Key Signals

• —Any DOJ or White House guidance formally terminating or restructuring the Anti-Weaponization Fund.
• —Updates on the scope, duration, and legal basis of the tax-filing probe restriction for Trump and his businesses.
• —Court filings or rulings that narrow or uphold the immunity arrangement.
• —Congressional follow-up: additional subpoenas, hearings, or proposed legislation targeting the immunity framework.